267 related articles for article (PubMed ID: 21229994)
1. H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor.
Hossain MA; Man BC; Zhao C; Xu Q; Du XJ; Wade JD; Samuel CS
Biochemistry; 2011 Mar; 50(8):1368-75. PubMed ID: 21229994
[TBL] [Abstract][Full Text] [Related]
2. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.
Chow BS; Chew EG; Zhao C; Bathgate RA; Hewitson TD; Samuel CS
PLoS One; 2012; 7(8):e42714. PubMed ID: 22936987
[TBL] [Abstract][Full Text] [Related]
3. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2.
Mookerjee I; Hewitson TD; Halls ML; Summers RJ; Mathai ML; Bathgate RA; Tregear GW; Samuel CS
FASEB J; 2009 Apr; 23(4):1219-29. PubMed ID: 19073841
[TBL] [Abstract][Full Text] [Related]
4. The anti-fibrotic actions of relaxin are mediated through AT
Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
[TBL] [Abstract][Full Text] [Related]
5. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway.
Heeg MH; Koziolek MJ; Vasko R; Schaefer L; Sharma K; Müller GA; Strutz F
Kidney Int; 2005 Jul; 68(1):96-109. PubMed ID: 15954899
[TBL] [Abstract][Full Text] [Related]
6. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo.
Samuel CS; Unemori EN; Mookerjee I; Bathgate RA; Layfield SL; Mak J; Tregear GW; Du XJ
Endocrinology; 2004 Sep; 145(9):4125-33. PubMed ID: 15155573
[TBL] [Abstract][Full Text] [Related]
7. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo.
Williams EJ; Benyon RC; Trim N; Hadwin R; Grove BH; Arthur MJ; Unemori EN; Iredale JP
Gut; 2001 Oct; 49(4):577-83. PubMed ID: 11559657
[TBL] [Abstract][Full Text] [Related]
8. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.
Pini A; Shemesh R; Samuel CS; Bathgate RA; Zauberman A; Hermesh C; Wool A; Bani D; Rotman G
J Pharmacol Exp Ther; 2010 Dec; 335(3):589-99. PubMed ID: 20826567
[TBL] [Abstract][Full Text] [Related]
9. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
[TBL] [Abstract][Full Text] [Related]
10. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling.
Sassoli C; Chellini F; Pini A; Tani A; Nistri S; Nosi D; Zecchi-Orlandini S; Bani D; Formigli L
PLoS One; 2013; 8(5):e63896. PubMed ID: 23704950
[TBL] [Abstract][Full Text] [Related]
11. Relaxin family peptide receptor-1 protects against airway fibrosis during homeostasis but not against fibrosis associated with chronic allergic airways disease.
Samuel CS; Royce SG; Chen B; Cao H; Gossen JA; Tregear GW; Tang ML
Endocrinology; 2009 Mar; 150(3):1495-502. PubMed ID: 18974264
[TBL] [Abstract][Full Text] [Related]
12. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
Grampp S; Goppelt-Struebe M
Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
[TBL] [Abstract][Full Text] [Related]
13. Relaxin Modulates the Expression of MMPs and TIMPs in Fibroblasts of Patients with Carpal Tunnel Syndrome.
Kang YM; Lee HM; Moon SH; Kang H; Choi YR
Yonsei Med J; 2017 Mar; 58(2):415-422. PubMed ID: 28120574
[TBL] [Abstract][Full Text] [Related]
14. Serelaxin inhibits the profibrotic TGF-β1/IL-1β axis by targeting TLR-4 and the NLRP3 inflammasome in cardiac myofibroblasts.
Cáceres FT; Gaspari TA; Samuel CS; Pinar AA
FASEB J; 2019 Dec; 33(12):14717-14733. PubMed ID: 31689135
[TBL] [Abstract][Full Text] [Related]
15. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis.
Hewitson TD; Ho WY; Samuel CS
Endocrinology; 2010 Oct; 151(10):4938-48. PubMed ID: 20826562
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of RXFP1 receptor contributes to the inefficacy of relaxin-based anti-fibrotic treatments in systemic sclerosis.
Corallo C; Pinto AM; Renieri A; Cheleschi S; Fioravanti A; Cutolo M; Soldano S; Nuti R; Giordano N
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):69-75. PubMed ID: 31365333
[TBL] [Abstract][Full Text] [Related]
17. Alterations of relaxin and its receptor system components in experimental diabetic cardiomyopathy rats.
Zhang X; Pan L; Yang K; Fu Y; Liu Y; Chen W; Ma X; Yin X
Cell Tissue Res; 2017 Nov; 370(2):297-304. PubMed ID: 28776188
[TBL] [Abstract][Full Text] [Related]
18. ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.
Kocan M; Sarwar M; Ang SY; Xiao J; Marugan JJ; Hossain MA; Wang C; Hutchinson DS; Samuel CS; Agoulnik AI; Bathgate RAD; Summers RJ
Sci Rep; 2017 Jun; 7(1):2968. PubMed ID: 28592882
[TBL] [Abstract][Full Text] [Related]
19. The chemically synthesized human relaxin-2 analog, B-R13/17K H2, is an RXFP1 antagonist.
Hossain MA; Samuel CS; Binder C; Hewitson TD; Tregear GW; Wade JD; Bathgate RA
Amino Acids; 2010 Jul; 39(2):409-16. PubMed ID: 20043231
[TBL] [Abstract][Full Text] [Related]
20. Improved chemical synthesis and demonstration of the relaxin receptor binding affinity and biological activity of mouse relaxin.
Samuel CS; Lin F; Hossain MA; Zhao C; Ferraro T; Bathgate RA; Tregear GW; Wade JD
Biochemistry; 2007 May; 46(18):5374-81. PubMed ID: 17425335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
